Detalles de la búsqueda
1.
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
Prostate
; 84(10): 954-958, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38641986
2.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate
; 84(3): 292-302, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37964482
3.
Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
Value Health
; 25(5): 796-802, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35500949
4.
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Prostate
; 81(16): 1382-1389, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34516663
5.
The Society for Integrative Oncology Practice Recommendations for online consultation and treatment during the COVID-19 pandemic.
Support Care Cancer
; 29(10): 6155-6165, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33852088
6.
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
BMC Cancer
; 20(1): 492, 2020 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32487038
7.
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Prostate
; 79(14): 1597-1603, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31361358
8.
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Lancet Oncol
; 19(1): 76-86, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29248236
9.
Risk factors for metastatic prostate cancer: A sentinel event case series.
Prostate
; 77(13): 1366-1372, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28786124
10.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
N Engl J Med
; 371(11): 1028-38, 2014 Sep 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25184630
11.
Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
Prostate
; 76(5): 512-20, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26689606
12.
Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.
BJU Int
; 117 Suppl 4: 17-34, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898239
13.
Challenges of conducting clinical trials of natural products to combat cancer.
Clin Adv Hematol Oncol
; 14(6): 447-55, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27379814
14.
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
Prostate
; 75(14): 1518-25, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26012728
15.
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Prostate
; 74(15): 1560-8, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25176007
16.
Therapeutic Approaches to Targeting Androgen Receptor Splice Variants.
Cells
; 13(1)2024 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38201308
17.
Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies.
JNCI Cancer Spectr
; 8(1)2024 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38070485
18.
Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors.
JCO Precis Oncol
; 8: e2300251, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394468
19.
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor.
bioRxiv
; 2024 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38405771
20.
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board.
Prostate Cancer Prostatic Dis
; 2024 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38172199